Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ewing sarcoma/PNET
Near ZIP Code:  within 500 miles of 61610
Results 1-21 of 21 for your search:
Start Over
Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1221, NCI-2014-02380, NCT02306161
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and over
Trial IDs: CL-PTL-121, NCI-2016-00417, NCT02511132
Erlotinib Hydrochloride and Temozolomide in Treating Younger Patients with Relapsed, Recurrent, or Refractory Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 201604002, NCI-2016-00549, NCT02689336
Cabozantinib-S-Malate in Treating Younger Patients with Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 30
Trial IDs: ADVL1622, NCI-2016-01258, NCT02867592
Olaparib and Temozolomide with or without Irinotecan Hydrochloride in Treating Patients with Recurrent or Metastatic Ewing Sarcoma Previously Treated with Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-115, NCI-2013-01821, NCT01858168
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 21 and under at diagnosis, any age at study entry
Trial IDs: ALTE03N1, NCI-2011-03822, CDR0000360708, COG-ALTE03N1, NCT00228787, NCT00082745
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Status: Active
Phase: No phase specified
Type: Tissue collection/Repository
Age: 21 and under
Trial IDs: AEWS07B1, NCI-2009-00370, CDR0000544202, COG-AEWS07B1, NCT00899990
Methionine-Labeled PET/CT in Detecting Tumors in Younger Patients with Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: Children and Young Adults
Trial IDs: METPET, NCI-2011-02414, NCT00840047
Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 5 to 21
Trial IDs: 201209088, NCI-2012-01541, NCT01661400
Molecular-Guided Therapy for Childhood Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 12 months to 21 years
Trial IDs: NMTRC009, NCI-2014-02270, NCT02162732
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients with Newly Diagnosed Bone or Soft Tissue Sarcomas
Status: Active
Phase: No phase specified
Type: Diagnostic
Age: Pediatric
Trial IDs: DWSARC, NCI-2015-00290, NCT02415816
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 9 and under
Trial IDs: NCH-15004, NCI-2016-01993, IRB15-00399, NCT02875314
Start Over